ES2579175T3 - Proceso para la producción de intermediarios de estetrol - Google Patents

Proceso para la producción de intermediarios de estetrol Download PDF

Info

Publication number
ES2579175T3
ES2579175T3 ES12729054.2T ES12729054T ES2579175T3 ES 2579175 T3 ES2579175 T3 ES 2579175T3 ES 12729054 T ES12729054 T ES 12729054T ES 2579175 T3 ES2579175 T3 ES 2579175T3
Authority
ES
Spain
Prior art keywords
formula
compound
reacting
alkyl
produce
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES12729054.2T
Other languages
English (en)
Spanish (es)
Inventor
Jean-Claude Pascal
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Estetra SRL
Original Assignee
Estetra SRL
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Estetra SRL filed Critical Estetra SRL
Application granted granted Critical
Publication of ES2579175T3 publication Critical patent/ES2579175T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07JSTEROIDS
    • C07J75/00Processes for the preparation of steroids in general
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07JSTEROIDS
    • C07J1/00Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 17 beta by a carbon atom, e.g. estrane, androstane
    • C07J1/0051Estrane derivatives
    • C07J1/0066Estrane derivatives substituted in position 17 beta not substituted in position 17 alfa
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07JSTEROIDS
    • C07J1/00Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 17 beta by a carbon atom, e.g. estrane, androstane
    • C07J1/0051Estrane derivatives
    • C07J1/0066Estrane derivatives substituted in position 17 beta not substituted in position 17 alfa
    • C07J1/007Estrane derivatives substituted in position 17 beta not substituted in position 17 alfa the substituent being an OH group free esterified or etherified
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/24Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/30Oestrogens
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07JSTEROIDS
    • C07J1/00Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 17 beta by a carbon atom, e.g. estrane, androstane
    • C07J1/0051Estrane derivatives
    • C07J1/0059Estrane derivatives substituted in position 17 by a keto group
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07JSTEROIDS
    • C07J13/00Normal steroids containing carbon, hydrogen, halogen or oxygen having a carbon-to-carbon double bond from or to position 17
    • C07J13/005Normal steroids containing carbon, hydrogen, halogen or oxygen having a carbon-to-carbon double bond from or to position 17 with double bond in position 16 (17)
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07JSTEROIDS
    • C07J51/00Normal steroids with unmodified cyclopenta(a)hydrophenanthrene skeleton not provided for in groups C07J1/00 - C07J43/00
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02PCLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00Technologies relating to chemical industry
    • Y02P20/50Improvements relating to the production of bulk chemicals
    • Y02P20/55Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Steroid Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
ES12729054.2T 2011-06-01 2012-06-01 Proceso para la producción de intermediarios de estetrol Active ES2579175T3 (es)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201161492300P 2011-06-01 2011-06-01
EP11168561 2011-06-01
EP11168561 2011-06-01
US201161492300P 2011-06-01
PCT/EP2012/060447 WO2012164096A1 (en) 2011-06-01 2012-06-01 Process for the production of estetrol intermediates

Publications (1)

Publication Number Publication Date
ES2579175T3 true ES2579175T3 (es) 2016-08-05

Family

ID=45003353

Family Applications (1)

Application Number Title Priority Date Filing Date
ES12729054.2T Active ES2579175T3 (es) 2011-06-01 2012-06-01 Proceso para la producción de intermediarios de estetrol

Country Status (24)

Country Link
US (1) US11053274B2 (enExample)
EP (1) EP2714710B1 (enExample)
JP (2) JP6425540B2 (enExample)
KR (1) KR101994805B1 (enExample)
CN (2) CN103703014A (enExample)
AU (1) AU2012264602B2 (enExample)
BR (1) BR112013030830B1 (enExample)
CA (1) CA2835981C (enExample)
CY (1) CY1118150T1 (enExample)
DK (1) DK2714710T3 (enExample)
EA (1) EA023991B1 (enExample)
ES (1) ES2579175T3 (enExample)
HR (1) HRP20160692T2 (enExample)
HU (1) HUE029252T2 (enExample)
ME (1) ME02454B (enExample)
MX (1) MX341561B (enExample)
PL (1) PL2714710T3 (enExample)
PT (1) PT2714710T (enExample)
RS (1) RS54880B1 (enExample)
SG (1) SG195118A1 (enExample)
SI (1) SI2714710T1 (enExample)
SM (1) SMT201600206B (enExample)
WO (1) WO2012164096A1 (enExample)
ZA (1) ZA201308446B (enExample)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11053274B2 (en) 2011-06-01 2021-07-06 Estetra S.P.R.L. Process for the production of estetrol intermediates
CA2835979C (en) 2011-06-01 2018-05-01 Estetra S.A. Process for the production of estetrol intermediates
EP2383279A1 (en) 2011-07-19 2011-11-02 Pantarhei Bioscience B.V. Process for the preparation of estetrol
EP2764008B1 (en) 2011-10-07 2016-08-17 Estetra S.P.R.L. Process for the production of estetrol
JP6813150B2 (ja) 2015-06-18 2021-01-13 エステトラ ソシエテ プリーヴ ア レスポンサビリテ リミテ エステトロールを含有する口腔内崩壊錠
CN116077454A (zh) 2015-06-18 2023-05-09 埃斯特拉有限责任公司 含雌四醇组分的口腔分散剂量单位
US11147771B2 (en) 2015-06-18 2021-10-19 Estetra Sprl Orodispersible dosage unit containing an estetrol component
ES2877186T3 (es) 2015-06-18 2021-11-16 Estetra Sprl Comprimido orodispersable que contiene estetrol
CN105837424A (zh) * 2016-03-31 2016-08-10 常州大学 一种1-氯-3-甲基-3-丁烯-2-酮的合成方法
CA3178291A1 (en) 2016-08-05 2018-04-12 Estetra Srl Method for the management of dysmenorrhea and menstrual pain
JP6935766B2 (ja) 2018-02-15 2021-09-15 日本精工株式会社 スピンドル装置
JOP20200260A1 (ar) 2018-04-19 2019-10-19 Estetra Sprl مركبات واستخداماتها للتخفيف من الأعراض المصاحبة لانقطاع الطمث
TWI801561B (zh) 2018-04-19 2023-05-11 比利時商依思特拉私人有限責任公司 化合物及其用於緩解絕經相關症狀的用途
IT201900017414A1 (it) 2019-09-27 2021-03-27 Ind Chimica Srl Processo per la preparazione di (15α,16α,17β)-estra-1,3,5(10)-triene-3,15,16,17-tetrolo (Estetrolo) ed intermedi di detto processo
IT201900021879A1 (it) 2019-11-22 2021-05-22 Ind Chimica Srl PROCESSO PER LA PREPARAZIONE DI (15α,16α,17β)-ESTRA-1,3,5(10)-TRIENE-3,15,16,17-TETROLO (ESTETROLO) ED INTERMEDI DI DETTO PROCESSO
UY38895A (es) 2019-09-27 2021-04-30 Ind Chimica Srl PROCESO PARA PREPARAR (15a,16a,17ß)-ESTRA-1,3,5(10)-TRIENO-3,15,16,17-TETROL (ESTETROL) E INTERMEDIOS DE DICHO PROCESO
TWI893101B (zh) 2020-04-16 2025-08-11 比利時商埃斯特拉有限責任公司 具有降低之副作用之避孕組成物
WO2023021026A1 (en) 2021-08-17 2023-02-23 Aspen Oss B.V. A synthetic pathway to estra-1,3,5(10)-triene-3,15a,16a,17b-tetrol
GB2626482B (en) 2021-10-01 2025-04-30 Ind Chimica Srl Process for preparing (15alpha,16alpha,17beta)-estra-1,3,5-(10)-triene-3,15,16,17-tetrol(estetrol) monohydrate
WO2024160373A1 (en) 2023-02-02 2024-08-08 Industriale Chimica S.R.L. PROCESS FOR PREPARING (15α,16α,17β)-ESTRA-1,3,5(10)-TRIENE-3,15,16,17-TETROL (ESTETROL) MONOHYDRATE

Family Cites Families (69)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE144266C (enExample)
US3138588A (en) 1962-08-24 1964-06-23 American Home Prod 17-ketals of estrone and derivatives thereof
US3177206A (en) 1963-03-07 1965-04-06 American Home Prod Selective bromination of a-ring aromatic 17-ketalized steroids
US3433785A (en) 1966-07-11 1969-03-18 Sterling Drug Inc 15,16-disubstituted aromatic steroids,intermediates and processes
US3673180A (en) 1970-06-18 1972-06-27 Merck & Co Inc 19-nor-6,6-ethylene-20-spiroxenes
US4792620A (en) 1983-10-14 1988-12-20 Bp Chemicals Limited Carbonylation catalysts
US4739078A (en) 1984-02-17 1988-04-19 The Upjohn Company Use of borohydride-salt lanthanide salt reagents for stereo selective reduction of C-15-keto prostaglandin precursors
IE60780B1 (en) 1987-01-23 1994-08-10 Akzo Nv New 11-aryl steroid derivatives
DE3710728A1 (de) 1987-03-31 1988-10-13 Schering Ag Verfahren zur herstellung von 17(alpha)-ethinyl-17ss-hydroxy-18-methyl-4,15-estradien-3-on und die neuen zwischenprodukte fuer dieses verfahren
US5073374A (en) 1988-11-30 1991-12-17 Schering Corporation Fast dissolving buccal tablet
US5340586A (en) 1991-04-12 1994-08-23 University Of Southern California Methods and formulations for use in treating oophorectomized women
JPH07101977A (ja) 1993-10-05 1995-04-18 Kureha Chem Ind Co Ltd ホルモン作用を軽減した新規なエストラジオール誘導体及びその増殖因子阻害剤
WO1997004752A1 (en) 1995-07-26 1997-02-13 Duramed Pharmaceuticals, Inc. Pharmaceutical compositions of conjugated estrogens and methods for their use
US6117446A (en) 1999-01-26 2000-09-12 Place; Virgil A. Drug dosage unit for buccal administration of steroidal active agents
TW548277B (en) 1999-07-16 2003-08-21 Akzo Nobel Nv Orally active androgens
US20020132801A1 (en) 2001-01-11 2002-09-19 Schering Aktiengesellschaft Drospirenone for hormone replacement therapy
EP1260225A1 (en) 2001-05-18 2002-11-27 Pantarhei Bioscience B.V. A pharmaceutical composition for use in hormone replacement therapy
US8048869B2 (en) 2001-05-18 2011-11-01 Pantarhei Bioscience B.V. Pharmaceutical composition for use in hormone replacement therapy
DK1390042T3 (da) 2001-05-23 2008-03-31 Pantarhei Bioscience Bv System for administration af et lægemiddel omfattende tetrahydroxyleret östrogen til anvendelse i hormonal svangerskabsforebyggelse
ES2337129T3 (es) 2001-05-23 2010-04-21 Pantarhei Bioscience B.V. Sistema de administracion de medicamento comprendiendo un estrogeno tetrahidroxilado para el uso en la anticoncepcion hormonal.
WO2003018026A1 (en) 2001-08-31 2003-03-06 Pantarhei Bioscience B.V. Use of estrogenic compounds in combination with progestogenic compounds in hormone-replacement therapy
WO2003041718A1 (en) 2001-11-15 2003-05-22 Pantarhei Bioscience B.V. Use of estrogenic compounds in combination with progestogenic compounds in hormone-replacement therapy
US6723348B2 (en) 2001-11-16 2004-04-20 Ethypharm Orodispersible tablets containing fexofenadine
HU227198B1 (en) 2001-11-27 2010-10-28 Richter Gedeon Nyrt Pharmaceutical composition for emergency contraception containing levonorgestrel
DK1478373T3 (da) 2002-02-21 2007-01-15 Schering Ag Farmaceutisk præparat omfattende ét eller flere steroider, én eller flere tetrahydrofolatbestanddele og vitamin B 12
US20050147670A1 (en) 2002-05-29 2005-07-07 Impax Laboratories Inc. Oral disintegrating dosage forms
CN100352445C (zh) 2002-06-11 2007-12-05 潘塔希生物科学股份有限公司 一种皮肤护理组合物及其用途
CN1691947B (zh) 2002-06-11 2011-11-23 潘塔希生物科学股份有限公司 雌激素成分在制备用于治疗或预防免疫介导的疾病中的应用以及包含所述雌激素成分的药物组合物
ES2299730T3 (es) 2002-07-12 2008-06-01 Pantarhei Bioscience B.V. Composicion farmaceutica que comprende derivados de estetrol para el uso en la terapia del cancer.
CA2503549C (en) 2002-10-23 2012-07-10 Pantarhei Bioscience B.V. Pharmaceutical compositions comprising estetrol derivatives for use in cancer therapy
ATE469165T1 (de) 2002-11-08 2010-06-15 Pantarhei Bioscience Bv Synthese von oestetrol aus von oestron abgeleiteten steroiden
ES2274456T3 (es) 2003-05-22 2007-05-16 Pantarhei Bioscience B.V. Uso de composiciones que comprenden un componente estrogenico para el tratamiento y la prevencion del dolor musculoesqueletico.
ZA200709854B (en) 2005-05-26 2009-03-25 Solvay Pharm Gmbh 17ß-HSD1 and STS inhibitors
DE112006002611A5 (de) 2005-07-25 2008-07-03 Technische Universität Dresden Rna-abhängige rna-polymerase, verfahren und kits zur amplifikation und / oder markierung von rna
US20070048369A1 (en) 2005-08-26 2007-03-01 National Starch And Chemical Investment Holding Corporation Mucosal delivery tablet
CA2636638C (en) 2006-01-09 2014-02-18 Pantarhei Bioscience B.V. A method of treating an acute vascular disorder
US20080113953A1 (en) 2006-06-08 2008-05-15 Warner Chilcott Company, Inc. Methods to administer solid dosage forms of ethinyl estradiol and prodrugs thereof with improved bioavailability
EP2029146B8 (en) 2006-06-08 2018-02-21 Allergan Pharmaceuticals International Limited Methods to administer solid dosage forms of ethinyl estradiol and prodrugs thereof with improved bioavailabilty
US20070286819A1 (en) 2006-06-08 2007-12-13 Warner Chilcott Company, Inc. Methods to administer ethinyl estradiol and prodrugs thereof with improved bioavailability
GB0621926D0 (en) 2006-11-03 2006-12-13 Medlock Medical Ltd Multi directional stretch tubular bandages
CL2007003429A1 (es) 2006-11-29 2008-04-11 Wyeth Corp Tableta bi-capa que comprende una primera capa con al menos un estrogeno y una segunda capa con uno o mas agentes terapeuticos seleccionados entre un modulador selectivo del receptor de estrogeno y un agente progestacional; proceso de produccion, uti
WO2008079245A2 (en) 2006-12-20 2008-07-03 Duramed Pharmaceuticals, Inc. Orally disintegrating solid dosage forms comprising progestin and methods of making and use thereof
ATE473746T1 (de) 2007-01-08 2010-07-15 Pantarhei Bioscience Bv Verfahren zur behandlung oder prävention von unfruchtbarkeit bei weiblichen säugern und pharmazeutisches kit zur anwendung dieses verfahrens
CL2008000095A1 (es) 2007-01-12 2008-05-16 Wyeth Corp Composicion de tableta en tableta que comprende una tableta central con estrogenos, un rellenador/diluyente, un rellenador/aglomerante, un componente polimerico y una capa de tableta exterior comprimida con agentes terapeuticos, un rellenador/diluyen
ATE537833T1 (de) 2007-06-21 2012-01-15 Pantarhei Bioscience Bv Behandlung des mekoniumaspirationssyndroms mit östrogenen
EP2170346B1 (en) 2007-07-19 2011-11-16 Pantarhei Bioscience B.V. Treatment or prevention of hypertensive disorders of pregnancy or fetal growth retardation
JPWO2009028676A1 (ja) 2007-08-31 2010-12-02 国立大学法人名古屋大学 カルボニル化合物の製造方法およびカルボニル化合物の製造に用いる酸化促進剤
EP2077272A1 (en) 2007-12-21 2009-07-08 Affibody AB Polypeptide libraries with a predetermined scaffold
EP2077273B1 (en) 2007-12-31 2011-09-14 Animal Technology Institute Taiwan Methods for separating casein from soluble proteins in a composition
US20110250274A1 (en) 2008-09-19 2011-10-13 Shaked Ze Ev Estriol formulations
DE102009007771B4 (de) 2009-02-05 2012-02-16 Bayer Schering Pharma Aktiengesellschaft Bukkales Applikationssystem, 17α-Estradiol enthaltend
CN102058604A (zh) 2009-11-17 2011-05-18 北京万全阳光医学技术有限公司 一种含有地诺孕素和戊酸雌二醇的药物组合物及其制备方法
US9603860B2 (en) 2010-07-28 2017-03-28 Laboratorios Leon Farma Sa Pharmaceutical compositions comprising active drugs, contraceptive kits comprising active drugs, and methods of administering the same
CA2835979C (en) 2011-06-01 2018-05-01 Estetra S.A. Process for the production of estetrol intermediates
US11053274B2 (en) 2011-06-01 2021-07-06 Estetra S.P.R.L. Process for the production of estetrol intermediates
EP2383279A1 (en) * 2011-07-19 2011-11-02 Pantarhei Bioscience B.V. Process for the preparation of estetrol
US10179107B2 (en) 2011-07-19 2019-01-15 Pantarhei Bioscience B.V. Tablet containing dehydroepiandrosterone (DHEA)
LT2741824T (lt) 2011-08-11 2017-06-26 Estetra S.P.R.L. Estetrolio panaudojimas kaip skubaus kontraceptiko
WO2013037708A1 (en) 2011-09-16 2013-03-21 Ferring B.V. A fast dissolving pharmaceutical composition
EP2764008B1 (en) 2011-10-07 2016-08-17 Estetra S.P.R.L. Process for the production of estetrol
EP2653163A1 (en) 2012-04-19 2013-10-23 Université de Liège Estrogenic components for use in the treatment of neurological disorders
US9808470B2 (en) 2012-04-19 2017-11-07 Universite De Liege Estrogenic components for use in the treatment of neurological disorders
WO2014159377A1 (en) 2013-03-14 2014-10-02 Teva Women's Health, Inc. Compositions containing tanaproget and natural estrogens
CA2924255C (en) 2013-09-18 2022-11-22 Crystal Pharma, S.A.U. Process for the preparation of estetrol
NZ720906A (en) 2013-12-12 2022-04-29 Estetra Sprl Orally disintegrating solid dosage unit containing an estetrol component
JP6813150B2 (ja) 2015-06-18 2021-01-13 エステトラ ソシエテ プリーヴ ア レスポンサビリテ リミテ エステトロールを含有する口腔内崩壊錠
US11147771B2 (en) 2015-06-18 2021-10-19 Estetra Sprl Orodispersible dosage unit containing an estetrol component
ES2877186T3 (es) 2015-06-18 2021-11-16 Estetra Sprl Comprimido orodispersable que contiene estetrol
CN116077454A (zh) 2015-06-18 2023-05-09 埃斯特拉有限责任公司 含雌四醇组分的口腔分散剂量单位

Also Published As

Publication number Publication date
MX341561B (es) 2016-08-25
BR112013030830B1 (pt) 2019-12-03
WO2012164096A1 (en) 2012-12-06
ZA201308446B (en) 2016-08-31
US11053274B2 (en) 2021-07-06
CY1118150T1 (el) 2017-06-28
KR101994805B1 (ko) 2019-07-01
BR112013030830A2 (pt) 2016-08-30
RS54880B1 (sr) 2016-10-31
SMT201600206B (it) 2016-08-31
CN103703014A (zh) 2014-04-02
DK2714710T3 (en) 2016-06-27
JP6425540B2 (ja) 2018-11-21
PL2714710T3 (pl) 2017-03-31
CA2835981A1 (en) 2012-12-06
EP2714710B1 (en) 2016-04-06
SI2714710T1 (sl) 2016-08-31
CN107266514A (zh) 2017-10-20
HUE029252T2 (en) 2017-02-28
JP6479912B2 (ja) 2019-03-06
EP2714710A1 (en) 2014-04-09
SG195118A1 (en) 2013-12-30
US20140107358A1 (en) 2014-04-17
CA2835981C (en) 2018-07-24
MX2013014045A (es) 2014-08-22
NZ617613A (en) 2015-12-24
AU2012264602B2 (en) 2017-03-09
JP2018024673A (ja) 2018-02-15
KR20140036205A (ko) 2014-03-25
HRP20160692T1 (hr) 2016-08-12
ME02454B (me) 2016-09-20
JP2014518199A (ja) 2014-07-28
EA023991B1 (ru) 2016-08-31
EA201301316A1 (ru) 2014-04-30
PT2714710T (pt) 2016-07-12
HRP20160692T2 (hr) 2016-09-23

Similar Documents

Publication Publication Date Title
ES2579175T3 (es) Proceso para la producción de intermediarios de estetrol
ECSP12012293A (es) Ciertas amino-pirimidinas, composicioines de las mismas y métodos para el uso de los mismos
ECSP12012292A (es) Ciertas amino-piridazinas, composicioines de las mismas y métodos de uso de los mismos
MX348917B (es) Proceso para la producción de estetrol.
AR098912A1 (es) Inhibidores de syk
UY33950A (es) Inhibidores de benzodioxano de la producciòn de leucotrieno
UY35641A (es) PROCEDIMIENTO DE SÍNTESIS PARA PREPARAR ANÁLOGOS MACROCÍCLICOS C1-CETO DE HALICONDRINA B, E INTERMEDIARIOS ÚTILES INCLUYENDO INTERMEDIARIOS CONTENIENDO GRUPOS ?SO2-(p-TOLILO)
EP2930179A4 (en) RUTHENIUM COMPLEX AND METHOD FOR THE PRODUCTION THEREOF, AND METHOD FOR THE PRODUCTION OF A RUTHENIA-CONTAINING THIN LAYER
PH12022552034A1 (en) Pyridone derivative having tetrahydropyranyl methyl group
UY34006A (es) Imidazopiridazinas
CR20150268A (es) Compuestos novedosos
MX2015017870A (es) Procedimiento para producir 4-propargilado amino-benzoxazinonas.
CR20160030A (es) Nuevos compuestos isoindolina o isoquinolina, un proceso para su preparación y composiciones farmacéuticas que los contienen
NI201400021A (es) Derivados de anilina, su preparación y su aplicación terapéutica.
UY37932A (es) Proceso para producir compuestos de piridazinona herbicidas
ES2603227T3 (es) Proceso para la preparación de compuestos cetólidos
UA111333C2 (uk) Спосіб одержання l-аргінінової солі периндроприлу
AR086987A1 (es) 1-piperazino-3-fenil-indanos deuterados para el tratamiento de esquizofrenia
AR077332A1 (es) Procesos para la alquilacion de pirazoles
MX2020004348A (es) Métodos de síntesis química de compuestos de diaminofenotiazinio que incluyen cloruro de metiltioninio (mtc).
EA201690467A1 (ru) Промышленный способ синтеза улипристала ацетата и его 4'-ацетильного аналога
RU2013136474A (ru) 2-меркаптобензтеллуразолы и способ их получения
EP2868653A4 (en) METHOD FOR PRODUCING A LIP WITH TERTIARY AMINOGRUPPE
UY37211A (es) Proceso para la preparacion de piridinilimidazolonas
EP3409681A4 (en) N, N-BIS (2-DIALKYL PHOSPHINOETHYL) AMINE-BORAN COMPLEX AND METHOD OF MANUFACTURING THEREOF AND METHOD FOR PRODUCING A RUTENHENIUM COMPLEX WITH N, N-BIS (2-DIALKYL PHOSPHINOETHYL) AMINE AS LIGAND